When was Intercept Pharmaceuticals founded?

Intercept Pharmaceuticals was founded in 2002 and raised its 1st funding round 4 years after it was founded.

Where is Intercept Pharmaceuticals located?

Intercept Pharmaceuticals is headquartered in New York City, United States. It is registered at New York, New York.

How many employees does Intercept Pharmaceuticals have?

As of Sep 30, 2026, the latest employee count at Intercept Pharmaceuticals is 244.

Is Intercept Pharmaceuticals a funded company?

Intercept Pharmaceuticals is a funded company, having raised a total of $121M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 16, 2006.

How much is Intercept Pharmaceuticals worth?

The last known valuation of Intercept Pharmaceuticals was $***** as of Mar 01, 2026.

When was the latest funding round of Intercept Pharmaceuticals?

Intercept Pharmaceuticals' latest funding was a $***** Post IPO round on Aug 2021, with participation from 0 investor. Its primary sector is Metabolic Diseases. In United States, the Metabolic Diseases sector has seen $1.36B in funding in 2026 to date.

Where does Intercept Pharmaceuticals rank among its competitors?

Intercept Pharmaceuticals ranks 23rd amongst 132 active competitors, of which 44 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Drug Farm, which secured $55M in Jul, 2026.

Who are the top competitors of Intercept Pharmaceuticals?

Intercept Pharmaceuticals' top competitors include Drug Farm, Nimbus Therapeutics and Mirum Pharmaceuticals. Among them, Drug Farm secured the most recent funding round in July, 2026.

Intercept Pharmaceuticals - 2026 Company Profile, Funding & Competitors

Company Details

Developer of therapeutics to treat progressive non-viral liver diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic liver diseases such as Nonalcoholic steatohepatitis (NASH), and Primary sclerosing cholangitis. FXR is a nuclear receptor expressed in the liver, intestine, kidney, and adipose tissue. FXR regulates a wide variety of target genes critically involved in the control of BA synthesis and transport, Lipid metabolism, and Glucose homeostasis.

Website: www.interceptpharma.com/
Registered Address: New York, New York

Key Metrics

Founded Year

2002

Location

New York City, United States

Stage

Acquired

Total Funding

$121M in 5 rounds

Latest Funding Round

Post IPO, Aug 2021, $*****

Last Known Valuation

$***** as on Mar 01, 2026

Investors

Orbimed & 8 more

Ranked

23^rd among 132 active competitors

Employee Count

244 as on Sep 30, 2026

Similar Companies

Drug Farm & 84 more

Exit Details

Acquired by Alfasigma (Sep 26, 2023)

View Intercept Pharmaceuticals' full profile

Intercept Pharmaceuticals is associated with 6 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Intercept Pharmaceuticals, Inc. CIN: 154058292 , United States, Active	Mar 26, 2019	-	-	-
Intercept Pharmaceuticals, Inc. CIN: 597241 , United States, Active	Mar 26, 2019	-	-	-
Intercept Pharma Danmark ApS CIN: 37104469 , Denmark, Deadpooled	Sep 22, 2015	-	-
ADVANZ PHARMA UK AND IRELAND LIMITED CIN: 9793586 , United Kingdom, Active	Sep 23, 2015	£10M - £50M (As on Dec 31, 2023)	13 (As on Dec 31, 2023)
Intercept Pharmaceuticals Inc CIN: 1270073 , United States, Active	Sep 03, 2002	$100M - $500M (As on Dec 31, 2022)	341 (As on Dec 31, 2022)	-
Intercept Pharmaceuticals, Inc. CIN: 223868459 , United States, Active	Dec 31, 1999	-	250 (As on Dec 31, 2024)	-

Intercept Pharmaceuticals got acquired by Alfasigma on Sep 26, 2023 at an acquisition amount of $*****.

Click here to take a look at Intercept Pharmaceuticals's acquisition in detail

Intercept Pharmaceuticals has raised a total funding of $121M over 5 rounds. Its first funding round was on May 16, 2006. Intercept Pharmaceuticals has 9 institutional investors.

Here is the list of recent funding rounds of Intercept Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 2021	2717472	Post IPO	7145256	1044923	6816609	2979390
Sep 04, 2012	2779017	Series C	4809672	9370459	8957975	Genextra
Jan 25, 2010	8858072	Series B	6000653	7200976	7433673	Genextra

Access funding benchmarks and valuations. Sign up today!

View details of Intercept Pharmaceuticals's funding rounds and investors

Intercept Pharmaceuticals' employee count trend

Intercept Pharmaceuticals has 244 employees as of Sep 26. Here is Intercept Pharmaceuticals's employee count trend over the years:

Employee count trend for Intercept Pharmaceuticals

Uncover Intercept Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Intercept Pharmaceuticals include Drug Farm, Nimbus Therapeutics and Mirum Pharmaceuticals. Here is the list of Top 10 competitors of Intercept Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Drug Farm 2015, Shanghai (China), Series D	Developer of a novel treatment for metabolic diseases	$138M	Shanghai Pudong Leading Area Investment Center, Zhejiang Private Enterprise United Investment ... & 13 others	65/100
2nd	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	64/100
3rd	Mirum Pharmaceuticals 2018, Menlo Park (United States), Public	Developer of small molecule based therapeutics to treat rare diseases	$120M	New Enterprise Associates, Oberland Capital ... & 9 others	63/100
4th	Aligos Therapeutics 2018, San Francisco (United States), Public	Developer of therapies to treat hepatologic diseases and viral infections	$225M	Wellington, Pivotal bioVenture Partners & 7 others	62/100
5th	Madrigal Pharmaceuticals 2011, Conshohocken (United States), Acquired	Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis	$38.4M	HarbourVest Partners, Avoro Capital & 3 others	62/100
6th	Altimmune 1997, Gaithersburg (United States), Acquired	Developer of vaccines for infectious disease including influenza, hepatitis B and solid tumors	$58M	Gershon Capital, Fidelis Capital & 15 others	62/100
7th	Enyo Pharma 2014, Lyon (France), Series C	Developer of therapeutics for diseases with impaired kidney function	$120M	Orbimed, Morningside & 9 others	62/100
8th	Akero Therapeutics 2017, San Francisco (United States), Acquired	Developer of small molecule therapeutics for metabolic disorders	$135M	Atlas Venture, Janus Henderson Investors ... & 13 others	62/100
9th	Inventiva Pharma 2012, Daix (France), Public	Provider of therapeutic solutions for fibrosis, lysosomal storage disorders and oncology	-	BVF Partners, Samsara BioCapital & 11 others	61/100
10th	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	60/100
23rd	Intercept Pharmaceuticals 2002, New York City (United States), Acquired	Developer of therapeutics to treat progressive non-viral liver diseases	$121M	New Leaf Venture Partners, Aisling Capital ... & 7 others	55/100